公开(公告)号：US12036213B2

公开(公告)日：2024-07-16

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61K9/00 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

CPC classification number: A61K31/451 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.

公开(公告)号：US20210275512A1

公开(公告)日：2021-09-09

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61P25/14 ,  A61K45/06 ,  A61P25/16 ,  A61K9/00

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia

公开(公告)号：US11738012B2

公开(公告)日：2023-08-29

申请号：US16078929

申请日：2017-02-24

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Hermann Kurt Russ ,  Michal Geva ,  Ralph Laufer ,  Aric Orbach

IPC: A61K31/451 ,  A61K45/06 ,  A61P27/02 ,  A61P27/06

CPC classification number: A61K31/451 ,  A61K45/06 ,  A61P27/02 ,  A61P27/06

Abstract: The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.

公开(公告)号：US11000519B2

公开(公告)日：2021-05-11

申请号：US16436947

申请日：2019-06-11

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/445 ,  A61K31/451 ,  A61P25/14 ,  A61K45/06 ,  A61P25/16 ,  A61K9/00 ,  A61K31/198

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.

公开(公告)号：US20220062255A1

公开(公告)日：2022-03-03

申请号：US17513239

申请日：2021-10-28

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Hermann Kurt Russ ,  Ralph Laufer ,  Aric Orbach

IPC: A61K31/451 ,  A61P27/06 ,  A61K9/00

Abstract: This application provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject, pharmaceutical composition and uses and applications thereof.